A Study to Evaluate Safety and Immunogenicity of AERAS-402

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

March 31, 2012

Conditions
Tuberculosis
Interventions
BIOLOGICAL

AERAS 402

0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28

BIOLOGICAL

Placebo

0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28

Trial Locations (1)

Unknown

Lotus Labs, Bangalore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aeras

OTHER